Liraglutide (Saxenda / Victoza)
Daily GLP-1 receptor agonist. FDA-approved 2010 (Victoza, T2D) and 2014 (Saxenda, obesity). The first wave of modern GLP-1 weight-loss therapy and direct predecessor to Semaglutide.
Liraglutide (Saxenda / Victoza): Daily GLP-1 receptor agonist. FDA-approved 2010 (Victoza, T2D) and 2014 (Saxenda, obesity). The first wave of modern GLP-1 weight-loss therapy and direct predecessor to Semaglutide. Liraglutide is the daily-injection GLP-1 that came before Semaglutide.
Liraglutide is the daily-injection GLP-1 that came before Semaglutide. Sold as Saxenda for weight loss and Victoza for diabetes. Same family as Wegovy/Ozempic but you inject it every day instead of weekly. Less convenient, but covered by some insurance plans that don't cover the weekly versions.
Approved as Victoza (2010, type 2 diabetes) and Saxenda (2014, obesity). Both Novo Nordisk.
FDA-approved drug products containing this substance are available. Compounded versions are not FDA-approved.
Yes, primary care, endocrinology, and obesity-medicine specialists prescribe widely.
Who it's for
- โPatients on insurance plans that cover Saxenda but not Wegovy
- โUsers who don't tolerate weekly Semaglutide titration
- โEducational reference for the GLP-1 class lineage
What to expect
- Week 1
Appetite drops. Mild nausea common.
- Week 4
First titration step. ~2-4 lb down typical.
- Week 8
Cumulative loss 5-10 lb for most users.
Looking at Liraglutide (Saxenda / Victoza)? Your next 3 steps
- 1Work out your syringe units
Vial size + BAC water turns into the exact units to draw for Liraglutide (Saxenda / Victoza).
Open calculator โ - 2See what to stack & monitor
The companion supplements and the bloodwork worth tracking on this kind of protocol.
Bloodwork guide โ - 3Save it & ask the Coach
A free account gets you Coach questions every day, free; membership saves your stack and makes the Coach stack-aware.
Create free account โ
How it works (mechanism)
Daily-injection GLP-1 agonist with fatty-acid modification that allows albumin binding for ~13-hour half-life. Same receptor as Semaglutide; shorter duration means daily injection.
Dosing protocol
Stacks well with
Side effects
When NOT to use
- โ MTC / MEN-2 history (boxed warning)
- โ Pancreatitis history
- โ Pregnancy / nursing
- โ Severe hypersensitivity
Bloodwork to monitor
- โข Lipid panel
- โข ALT/AST
- โข A1C if metabolic context
Common mistakes
- โข Skipping titration steps
- โข Treating it as Semaglutide-equivalent (daily vs weekly is a real burden difference)
- โข Stopping abruptly without a maintenance plan
What it actually is
Liraglutide is a daily GLP-1 injection, approved in 2010 as Victoza for type 2 diabetes and in 2014 as Saxenda for weight management. It is the direct predecessor of semaglutide and the first of the modern GLP-1 drugs to reach the obesity market. Generic versions have begun to appear as the original patents expire.
Liraglutide carries the same GLP-1 signal as semaglutide, with a fatty acid chain attached that binds it to albumin in the blood and slows its clearance. That extends the half-life from a couple of minutes to about 13 hours, which is long enough for daily dosing but not weekly. Everything else is the class effect: earlier fullness, slower stomach emptying, less food noise.
Forms, and which is which
The higher-dose label. Titrated weekly from 0.6 mg to 3.0 mg daily.
Verdict: The obesity-indicated form.
Lower ceiling dose, the original approval. Same molecule as Saxenda under a different indication and dose ceiling.
Verdict: Same molecule, lower dose, different label.
A Victoza-reference generic was approved in 2024 and a Saxenda-reference generic in 2025. They carry the labelled indications of their respective reference products, which are not the same โ the diabetes generic is not an obesity product.
Verdict: Approved alternatives, each tied to its own indication.
Makes no sense here โ a pharmacy generic of the same molecule exists and is inspected.
Verdict: Taking a quality risk for no reason.
What it is claimed to do, graded
The SCALE trial is randomised and placebo-controlled: 63.2% of people on liraglutide 3.0 mg lost at least 5% of body weight and 33.1% lost more than 10%, against 27.1% and 10.6% on placebo. Real, and clearly a smaller effect than semaglutide or tirzepatide.
The original indication with a very large randomised base, over 500 RCTs indexed for this molecule.
The LEADER outcome trial demonstrated this in a high-risk diabetes population, and that is the labelled indication. It does not establish the same benefit from obesity-dose Saxenda in people without diabetes.
Mixed, and dose-dependent. In the diabetes-dose head-to-head, semaglutide produced MORE gastrointestinal adverse events and more discontinuations than liraglutide. At obesity doses, overall gastrointestinal and nausea rates were similar while discontinuation for adverse events was higher on liraglutide. Neither direction is a clean win.
Grades describe how much human evidence exists for that specific claim, not whether it will work for you or whether it is safe.
Pros and cons
- โข One of the longest real-world safety records in the class, and the longest among the obesity-indicated GLP-1 products โ exenatide, approved in 2005, predates it
- โข Cardiovascular outcome data behind it
- โข Generics now exist, so it is the cheapest legitimate GLP-1 route
- โข A shorter washout than the weekly agents, given a half-life of about 13 hours rather than about a week
- โข Clearly less effective for weight loss than semaglutide or tirzepatide
- โข Daily injection is a real adherence burden
- โข Daily nausea peaks rather than weekly ones, though head-to-head comparisons do not consistently favour either
- โข Gallbladder events increase with rapid weight loss
When to stop
- โข Severe persistent abdominal pain radiating to the back
- โข A new neck lump, hoarseness or difficulty swallowing
- โข Right upper abdominal pain with fever or jaundice
- โข Vomiting that prevents keeping fluids down
- โข Any serious allergic reaction, including swelling of the face, lips or throat
- โข A resting heart rate that climbs and stays up
- โข New or worsening vision changes โ rapid glucose improvement can transiently worsen diabetic retinopathy
- โข Pregnancy
Interactions
Additive glucose lowering with genuine hypoglycaemia risk.
Delayed gastric emptying can change absorption rate. Trials found no clinically relevant effect on the oral drugs tested, so this is monitoring for drugs where delayed absorption matters, not a universal spacing rule.
No added benefit, multiplied side effects.
Worsens nausea and hypoglycaemia risk.
Retained gastric contents despite fasting. Tell the anaesthetist.
Is this for you?
- โข Adults who meet the approved indications and are working with a prescriber
- โข Anyone weighing the class options with a clinician on their approved indications rather than on cost
- โข Personal or family history of medullary thyroid carcinoma or MEN-2
- โข You have had a serious hypersensitivity reaction to liraglutide or any ingredient in it
- โข You have severe gastroparesis โ labelling does not recommend use
- โข You are pregnant. A prior episode of pancreatitis needs a clinician's assessment rather than a decision made here
- โข You will not realistically inject every single day
The one number
Sources for the claims above
- Randomised controlled trial of liraglutide 3.0 mg in weight management (SCALE)
- Once-weekly semaglutide compared with once-daily liraglutide
- Discovery and development of the molecule
- Arcuate nucleus mediates liraglutide-dependent weight loss
Drug & supplement interactions
- โ Insulin and sulfonylureas: dose reduction usually needed to prevent hypoglycemia
- โ Slows gastric emptying, affects oral medication absorption
- โ Avoid alcohol during titration
Community patterns
New to Liraglutide (Saxenda / Victoza)? Grab the starter checklist.
Drop your email and we'll send the one-page starter checklist beginners actually need first. No account needed.
No spam, and we never sell your email. Just the checklist. Email support@pepdex.co to opt out any time.
Numbers redacted in this preview. Members get the full answer, on their own stack.
Ask the Coach anything about Liraglutide (Saxenda / Victoza) or your own stack. This is it working.
Trained only on Pepdex content. Does the dose math, flags interactions, knows your stack. Won't push vendors, won't pretend to be a doctor.
Unlock the full Coach, from $4.99/week โFrequently asked
What is Liraglutide (Saxenda / Victoza)?+
Is Liraglutide (Saxenda / Victoza) FDA approved?+
Is Liraglutide (Saxenda / Victoza) legal?+
Is Liraglutide (Saxenda / Victoza) banned by WADA?+
Are you still natty after taking Liraglutide (Saxenda / Victoza)?+
Do doctors prescribe Liraglutide (Saxenda / Victoza)?+
What's the typical dose of Liraglutide (Saxenda / Victoza)?+
What are the side effects of Liraglutide (Saxenda / Victoza)?+
How long until Liraglutide (Saxenda / Victoza) starts working?+
What can you stack with Liraglutide (Saxenda / Victoza)?+
Where do people get Liraglutide (Saxenda / Victoza)?+
Liraglutide (Saxenda / Victoza) vs Semaglutide, which is better?+
Liraglutide (Saxenda / Victoza) vs Tirzepatide, which is better?+
Common questions about Liraglutide (Saxenda / Victoza)
Head-to-head with Liraglutide (Saxenda / Victoza)
Tracked alongside Liraglutide (Saxenda / Victoza)
Same goal, different aisle โ each graded on its own evidence in the Pepdex catalog.
More in Fat Loss
Strong weight loss with a cleaner side effect profile than semaglutide. A dual agonist (GLP-1 + GIP), FDA-approved as Mounjaro / Zepbound.
The original weight-loss wave, sold as Ozempic / Wegovy. A GLP-1 agonist.
Triple agonist (GLP-1 + GIP + glucagon) from Eli Lilly. In trials it outperforms Tirzepatide for weight loss.
An appetite-control shot for weight loss. A long-acting amylin agonist that works on a different pathway than the GLP-1 drugs, often paired with Semaglutide as 'CagriSema' to break GLP-1 plateaus.